However, there are no strong clinical data to support the benefit of combinations of hypomethylating agents with FLT3 inhibitors in FLT3-mutated AML patients [6], and no clinical trial of these combinations has been carried out in AML patients with wtFLT3. This evidence concerns the gene FLT3 and acute myeloid leukemia.